- R&D Day to highlight the Company’s strategy on its leading clinical programs and emerging firs-in-class portfolio in immuno-oncology;
- Presentations by leading clinicians to feature the latest data on Tedopi® and BI 765063.
NANTES,
Date:
Time:
Details for the virtual R&D Day : |
The live webcast of the event will be available from at the following link: https://www.financelive.fr/oseo-immuno/inscription/ A replay of the webcast following the event will be available for 90 days on the Company’s website: https://ose-immuno.com/en/ |
The event, which will feature presentations by leading clinicians as well as key members of the
- The Company’s strategy to build a leading portfolio of best- and first-in-class cancer immunotherapies.
- OSE’s goal to position Tedopi® as a new standard of care in non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) failure and its ongoing clinical development as a maintenance therapy for ovarian and pancreatic cancers.
- Recent clinical data supporting development of first-in-class CD47/SIRPα pathway targeting antibody BI 765063 alone and in combination with anti-PD-1 ezabenlimab in solid tumours.
- OSE’s emerging best- and first-in-class immuno-oncology portfolio which includes a novel myeloid cell “Don’t Eat Me” signal targeting CLEC-1 and a bispecific antibody platform (BiCKI®) whose first candidate, BiCKI®-IL-7 both combines an anti-PD-1 and the cytokine signal interleukin-7 (IL-7).
Amongst the R&D Day’s key speakers are:
- Pr.
Benjamin Besse , Director of Clinical Research at Gustave Roussy (Villejuif,France ), will present the positive final results of the Phase 3 Tedopi® clinical program in NSCLC, calledAtalante -1, as well as an overview of the current landscape in NSCLC post-ICI. - Dr.
Philippe Cassier , Medical Oncologist atLeon Berard Cancer Center (Lyon, France ), will highlight Phase 1 results of BI 765063 alone and in combination with ezabenlimab.
ABOUT
Vaccine platform
- Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive final results of the Phase 3 trial (
Atalante 1) in Non-Small CellLung Cancer patients after secondary resistance to checkpoint inhibitors.
In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT. - CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021).
- BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with
Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy or in combination with ezabenlimab (PD-1 antagonist); Expansion Phase 1 open for screening. - CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
- BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Auto-immunity and inflammation platform
- FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the
Nantes University Hospital ); Phase 2-ready asset in an autoimmune disease indication. - OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
Servier ; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a is being conducted in Sjögren’s syndrome (Servier sponsor). - OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
For more information: https://ose-immuno.com/en/
Click and follow us on Twitter and Linkedln
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Contacts
Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations thomas.guillot@ose-immuno.com +33 607 380 431 | Media darren@lifescicomms.com +1 646 627 8387 French Media: FP2COM fportejoie@fp2com.fr +33 607 768 283 | gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the
Source:
2021 GlobeNewswire, Inc., source